Meeting
2017 Gastrointestinal Cancers Symposium
Resminostat and sorafenib combination therapy for advanced hepatocellular carcinoma in patients previously untreated with systemic chemotherapy.
Authors
Masatoshi Kudo
Kindai University Faculty of Medicine, Osaka, Japan
Masatoshi Kudo , Baek-Yeol Ryoo , Ho Yeong Lim , Do Young Kim , Takuji Okusaka , Masafumi Ikeda , Hisashi Hidaka , Jong-Eun Yeon , Eishiro Mizukoshi , Manabu Morimoto , Myung Ah Lee , Kohichiroh Yasui , Yasunori Kawaguchi , Jeong Heo , Sojiro Morita , Tae-You Kim , Junji Furuse , Kazuhiro Katayama , Takeshi Aramaki , Won-Young Tak
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Prevention, Diagnosis, and Screening
Clinical Trial Registration Number
NCT02400788
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 252)
DOI
10.1200/JCO.2017.35.4_suppl.252
Abstract #
252
Poster Bd #
B8
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Phase II study of pembrolizumab in advanced, unresectable hepatocellular carcinoma.
First Author: Lynn G. Feun
Poster
2018 Gastrointestinal Cancers Symposium
Phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma.
First Author: Sunyoung S. Lee
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Cabozantinib (CABO) tolerance and efficacy for patients with advanced hepatocellular carcinoma (HCC) after failure of sorafenib (SOR) in a French population: CLERANCE, a phase 4 trial.
First Author: Philippe Merle
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Sorafenib plus tislelizumab as maintenance therapy for patients with advanced hepatocellular carcinoma treated with transarterial chemoembolization: A phase II study.
First Author: Mingyue Cai